Many ocular diseases (e.g. Age-related Macular Degeneration, glaucoma) are starting with the degeneration of the retina cellular structure which is invisible to current examinations. The patented technology developed by EarlySight takes pictures and quantifies the retinal cells, and allows to have a ten times more detailed view of the retinal tissues. This is achieved by coupling an innovative illumination of the eye with key optical components. According to ophthalmologists, it will greatly improve the diagnosis and treatment follow-up by providing objective evidences of the disease progression.
Incorporated in 2019, EarlySight conducted a proof-of-concept study at the EPFL and has been working on a clinical-oriented prototype to perform the clinical validation. Also supported by the Gebert Rüf Foundation, EIT Health, Innogrant, Bridge (Innosuisse and the Swiss National Science Foundation), EarlySight has already initiated discussions with several pharmaceutical companies and ophthalmic centres in Europe.
The support of the FIT will help EarlySight to put their first product on the market. To this end, the clinical prototype needs to be finalized before requesting the CE marking. EarlySights expects to generate their first sales in 2021.
(Press release)
Picture: Mathieu KUNZI, Timothé LAFOREST (from left)
Please login or sign up to comment.
Commenting guidelines